COMPASS Pathways is a life sciences company that aims to accelerate patient access to evidence-based innovations in mental health.
The company recently launched a massive late-stage clinical study across Europe and North America to evaluate psilocybin in patients with treatment-resistant depression. With a Breakthrough Therapy designation from the FDA, the company hopes to accelerate the drug development process. The company also recently filed for a patent application.
The Breakthrough Therapy designation represents a significant milestone for psilocybin therapy and research. With about 100 million individuals around the world suffering from treatment-resistant depression, there's a significant unmet medical need.
Chairman, CEO and Co-Founder
Ekaterina Malievskaia MD, MScPH
Co-Founder & Chief Innovation Officer
Lars Christian Wilde
Co-Founder, President, Chief Business Officer